Prediction of IDH and TERT promoter mutations in low-grade glioma from magnetic resonance images using a convolutional neural network.

Journal: Scientific reports
Published Date:

Abstract

Identification of genotypes is crucial for treatment of glioma. Here, we developed a method to predict tumor genotypes using a pretrained convolutional neural network (CNN) from magnetic resonance (MR) images and compared the accuracy to that of a diagnosis based on conventional radiomic features and patient age. Multisite preoperative MR images of 164 patients with grade II/III glioma were grouped by IDH and TERT promoter (pTERT) mutations as follows: (1) IDH wild type, (2) IDH and pTERT co-mutations, (3) IDH mutant and pTERT wild type. We applied a CNN (AlexNet) to four types of MR sequence and obtained the CNN texture features to classify the groups with a linear support vector machine. The classification was also performed using conventional radiomic features and/or patient age. Using all features, we succeeded in classifying patients with an accuracy of 63.1%, which was significantly higher than the accuracy obtained from using either the radiomic features or patient age alone. In particular, prediction of the pTERT mutation was significantly improved by the CNN texture features. In conclusion, the pretrained CNN texture features capture the information of IDH and TERT genotypes in grade II/III gliomas better than the conventional radiomic features.

Authors

  • Ryohei Fukuma
    Department of Neurosurgery, Osaka University Graduate School of Medicine.
  • Takufumi Yanagisawa
    Department of Neurosurgery, Osaka University Graduate School of Medicine.
  • Manabu Kinoshita
    Department of Neurosurgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan. mail@manabukinoshita.com.
  • Takashi Shinozaki
    CiNet, National Institute of Information and Communications Technology, Japan.
  • Hideyuki Arita
    Department of Neurosurgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
  • Atsushi Kawaguchi
    Section of Clinical Cooperation System, Center for Comprehensive Community Medicine, Faculty of Medicine, Saga University, Saga, Japan.
  • Masamichi Takahashi
    Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
  • Yoshitaka Narita
    Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
  • Yuzo Terakawa
    Kansai Molecular Diagnosis Network for CNS Tumors, Osaka, 540-0006, Japan.
  • Naohiro Tsuyuguchi
    Kansai Molecular Diagnosis Network for CNS Tumors, Osaka, 540-0006, Japan.
  • Yoshiko Okita
    Department of Neurosurgery, Osaka International Cancer Institute, Osaka Prefectural Hospital Organization, Osaka, 541-8567, Japan.
  • Masahiro Nonaka
    Kansai Molecular Diagnosis Network for CNS Tumors, Osaka, 540-0006, Japan.
  • Shusuke Moriuchi
    Kansai Molecular Diagnosis Network for CNS Tumors, Osaka, 540-0006, Japan.
  • Masatoshi Takagaki
    Department of Neurosurgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
  • Yasunori Fujimoto
    Department of Neurosurgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
  • Junya Fukai
    Kansai Molecular Diagnosis Network for CNS Tumors, Osaka, 540-0006, Japan.
  • Shuichi Izumoto
    Kansai Molecular Diagnosis Network for CNS Tumors, Osaka, 540-0006, Japan.
  • Kenichi Ishibashi
    Kansai Molecular Diagnosis Network for CNS Tumors, Osaka, 540-0006, Japan.
  • Yoshikazu Nakajima
    Kansai Molecular Diagnosis Network for CNS Tumors, Osaka, 540-0006, Japan.
  • Tomoko Shofuda
    Kansai Molecular Diagnosis Network for CNS Tumors, Osaka, 540-0006, Japan.
  • Daisuke Kanematsu
    Kansai Molecular Diagnosis Network for CNS Tumors, Osaka, 540-0006, Japan.
  • Ema Yoshioka
    Kansai Molecular Diagnosis Network for CNS Tumors, Osaka, 540-0006, Japan.
  • Yoshinori Kodama
    Kobe University Graduate School of Medicine, Department of Diagnostic Pathology, 7-5-1 Kusunoki-cho Chuo-ku, Kobe, 650-0017, Japan.
  • Masayuki Mano
    Kansai Molecular Diagnosis Network for CNS Tumors, Osaka, 540-0006, Japan.
  • Kanji Mori
    Kansai Molecular Diagnosis Network for CNS Tumors, Osaka, 540-0006, Japan.
  • Koichi Ichimura
    Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.
  • Yonehiro Kanemura
    Kansai Molecular Diagnosis Network for CNS Tumors, Osaka, 540-0006, Japan.
  • Haruhiko Kishima
    Department of Neurosurgery, Osaka University Graduate School of Medicine.